A synthetic triterpenoid cddo-im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  So, Jae Young ^a   Lin, Janice J ^a   Wahler, Joseph ^a   Liby, Karen T ^b   Sporn, Michael B ^b   Suh, Nanjoo ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BARDOXOLONE IMIDAZOLE; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; SMAD PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRITERPENOID; UNCLASSIFIED DRUG; WNT PROTEIN; 1-(2-CYANO-3,12-DIOXOOLEANA-1,9-DIEN-28-OYL) IMIDAZOLE; IMIDAZOLE DERIVATIVE; NOTCH RECEPTOR; OLEANOLIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER SIZE; CANCER STEM CELL; CELL CULTURE; CELL SUBPOPULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; ANALOGS AND DERIVATIVES; CELL CYCLE CHECKPOINT; DOSE RESPONSE; DRUG EFFECTS; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; G2 PHASE CELL CYCLE CHECKPOINTS; HEDGEHOG PROTEINS; HUMANS; IMIDAZOLES; M PHASE CELL CYCLE CHECKPOINTS; NEOPLASTIC STEM CELLS; OLEANOLIC ACID; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84907199154     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107616     Document Type: Article

References (53)

1. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363: 1938-1948.
2. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, et al. (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30: 1879-1887.
3. Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A (2010) Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36: 206-215.
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
5. Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777-1785.
6. Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10: R25.
7. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679.
8. Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, et al. (2012) CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 43: 364-373.
9. Yin B, Ma ZY, Zhou ZW, Gao WC, Du ZG, et al. (2014) The TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model. Oncogene.
10. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, et al. (2006) Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66: 6063-6071.
11. Tanaka H, Nakamura M, Kameda C, Kubo M, Sato N, et al. (2009) The Hedgehog signaling pathway plays an essential role in maintaining the CD44+ CD24-/low subpopulation and the side population of breast cancer cells. Anticancer Res 29: 2147-2157.
12. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, et al. (2010) Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 70: 709-718.
13. Takebe N, Harris PJ, Warren RQ, Ivy SP (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8: 97-106.
14. Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, et al. (1999) A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res 59: 336-341.
15. Liby KT, Sporn MB (2012) Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev 64: 972-1003.
16. Place AE, Suh N, Williams CR, Risingsong R, Honda T, et al. (2003) The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 9: 2798-2806.
17. Samudio I, Konopleva M, Hail N, Jr., Shi YX, McQueen T, et al. (2005) 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. J Biol Chem 280: 36273-36282.
18. Liby K, Voong N, Williams CR, Risingsong R, Royce DB, et al. (2006) The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 12: 4288-4293.
19. Kim EH, Deng CX, Sporn MB, Liby KT (2011) CDDO-imidazolide induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells. Cancer Prev Res (Phila) 4: 425-434.
20. So JY, Wahler JE, Yoon T, Smolarek AK, Lin Y, et al. (2013) Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression. Cancer Prev Res (Phila) 6: 959-970.
21. Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, et al. (2005) Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res 65: 4799-4808.
22. Honda T, Honda Y, Favaloro FG, Jr., Gribble GW, Suh N, et al. (2002) A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg Med Chem Lett 12: 1027-1030.
23. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, et al. (2011) New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 74: 537-545.
24. Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, et al. (1999) Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer 81: 1328-1334.
25. So JY, Smolarek AK, Salerno DM, Maehr H, Uskokovic M, et al. (2013) Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS One 8: e54020.
26. So JY, Lee HJ, Smolarek AK, Paul S, Wang CX, et al. (2011) A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer. Mol Pharmacol 79: 360-367.
27. Lee HJ, Ju J, Paul S, So JY, DeCastro A, et al. (2009) Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-gamma. Clin Cancer Res 15: 4242-4249.
28. Lee HJ, Liu H, Goodman C, Ji Y, Maehr H, et al. (2006) Gene expression profiling changes induced by a novel Gemini Vitamin D derivative during the progression of breast cancer. Biochem Pharmacol 72: 332-343.
29. Rosen JM, Jordan CT (2009) The increasing complexity of the cancer stem cell paradigm. Science 324: 1670-1673.
30. Badve S, Nakshatri H (2012) Breast-cancer stem cells-beyond semantics. Lancet Oncol 13: e43-48.
31. Al-Hajj M, Clarke MF (2004) Self-renewal and solid tumor stem cells. Oncogene 23: 7274-7282.
32. Reynolds BA, Rietze RL (2005) Neural stem cells and neurospheres-re-evaluating the relationship. Nat Methods 2: 333-336.
33. Pastrana E, Silva-Vargas V, Doetsch F (2011) Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 8: 486-498.
34. Farnie G, Clarke RB (2007) Mammary stem cells and breast cancer-role of Notch signalling. Stem Cell Rev 3: 169-175.
35. Han J, Hendzel MJ, Allalunis-Turner J (2011) Notch signaling as a therapeutic target for breast cancer treatment? Breast Cancer Res 13: 210.
36. McGowan PM, Simedrea C, Ribot EJ, Foster PJ, Palmieri D, et al. (2011) Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res 9: 834-844.
37. Xiao Y, Ye Y, Zou X, Jones S, Yearsley K, et al. (2011) The lymphovascular embolus of inflammatory breast cancer exhibits a Notch 3 addiction. Oncogene 30: 287-300.
38. Ling H, Sylvestre JR, Jolicoeur P (2013) Cyclin D1-dependent induction of luminal inflammatory breast tumors by activated notch3. Cancer Res 73: 5963-5973.
39. Parr C, Watkins G, Jiang WG (2004) The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med 14: 779-786.
40. O'Neill CF, Urs S, Cinelli C, Lincoln A, Nadeau RJ, et al. (2007) Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth. Am J Pathol 171: 1023-1036.
41. Lee J, Sehrawat A, Singh SV (2012) Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells. Breast Cancer Res Treat 136: 45-56.
42. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
43. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, et al. (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3: e2888.
44. Zavadil J, Bottinger EP (2005) TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24: 5764-5774.
45. Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, et al. (2011) Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 9: 433-446.
46. Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL (2011) TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res 71: 4707-4719.
47. To C, Kulkarni S, Pawson T, Honda T, Gribble GW, et al. (2008) The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid-imidazolide alters transforming growth factor beta-dependent signaling and cell migration by affecting the cytoskeleton and the polarity complex. J Biol Chem 283: 11700-11713.
48. ten Haaf A, Bektas N, von Serenyi S, Losen I, Arweiler EC, et al. (2009) Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival. BMC Cancer 9: 298.
49. Xu L, Kwon YJ, Frolova N, Steg AD, Yuan K, et al. (2010) Gli1 promotes cell survival and is predictive of a poor outcome in ERalpha-negative breast cancer. Breast Cancer Res Treat 123: 59-71.
50. Goel HL, Pursell B, Chang C, Shaw LM, Mao J, et al. (2013) GLI1 regulates a novel neuropilin-2/alpha6beta1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO Mol Med 5: 488-508.
51. Liby K, Hock T, Yore MM, Suh N, Place AE, et al. (2005) The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 65: 4789-4798.
52. Alli E, Sharma VB, Sunderesakumar P, Ford JM (2009) Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 69: 3589-3596.
53. Hui L, Zheng Y, Yan Y, Bargonetti J, Foster DA (2006) Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene 25: 7305-7310.